WO2014042292A1 - Composition comprenant un activateur de la protéine kinase c destiné à favoriser l'adhérence de cellules souches et méthode destinée à favoriser l'adhérence de cellules souches - Google Patents

Composition comprenant un activateur de la protéine kinase c destiné à favoriser l'adhérence de cellules souches et méthode destinée à favoriser l'adhérence de cellules souches Download PDF

Info

Publication number
WO2014042292A1
WO2014042292A1 PCT/KR2012/007308 KR2012007308W WO2014042292A1 WO 2014042292 A1 WO2014042292 A1 WO 2014042292A1 KR 2012007308 W KR2012007308 W KR 2012007308W WO 2014042292 A1 WO2014042292 A1 WO 2014042292A1
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
activator
cells
adhesion
protein kinase
Prior art date
Application number
PCT/KR2012/007308
Other languages
English (en)
Korean (ko)
Inventor
황기철
장우철
Original Assignee
연세대학교 산학협력단
가톨릭대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단, 가톨릭대학교 산학협력단 filed Critical 연세대학교 산학협력단
Priority to PCT/KR2012/007308 priority Critical patent/WO2014042292A1/fr
Publication of WO2014042292A1 publication Critical patent/WO2014042292A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to a composition for promoting stem cell adhesion comprising a protein kinase C activator and a method for promoting the attachment of stem cells.
  • the present invention also relates to a stem cell promoted adhesion by protein kinase C activator, and a pharmaceutical composition for treating ischemic heart disease comprising the same as an active ingredient.
  • stem cells As an alternative to solve these problems, interest in stem cells has increased, and pluripotent stem cells with the ability to form all the organs through proliferation and differentiation are treated as well as most diseases, Parkinson's disease and various cancers. It has been suggested that it can be applied to a variety of treatments such as diabetes and spinal cord injury.
  • Stem cell refers to a cell that has the ability to self-replicate and differentiate into two or more new cells. Embryonic stem cells, induced pluripotent cells, and adults Stem cells (adult stem cells) and the like are the most actively studied. In the case of embryonic stem cells or induced pluripotent stem cells, there are still limitations in applying them to the clinic due to stability issues such as ethical issues and tumor formation. In the case of adult stem cells, clinical studies have been conducted in patients due to its stability, but in the case of neural stem cells and cord blood cells, adult cells are transplanted to themselves. Autograft is not yet possible and there is a limit to transplant the neural stem cells of others. Bone marrow or fat-derived mesenchymal stem cells are stem cells that are most actively studied in the clinic because they can be easily obtained from the human body.
  • Heart disease is one of the leading causes of death worldwide and one of the leading causes of death in recent years.
  • Myocardial injury by myocardial infarction leads to irreversible loss of tissue and cardiac dysfunction, and the remaining cardiomyocytes in the damaged tissue are gradually replaced by fibroblasts trying to form scar tissue.
  • medical and device-based therapies can ameliorate the symptoms of these heart diseases, the limitations of treatment appear in that they cannot reverse the loss of cardiomyocytes, the root cause of the problem. Therefore, there have been attempts to transplant embryonic stem cells or cardiomyocytes as a treatment for regenerating damaged cardiomyocytes.However, transplantation of cardiomyocytes has difficulty in cell acquisition, and in the case of embryonic stem cells, problems such as tumor formation and immunorejection are difficult. It is not yet known how to regenerate cardiomyocytes effectively.
  • Bone marrow-derived mesenchymal stem cells can differentiate into cardiomyocytes, endothelial cells and smooth muscle cells when externally stimulated, and several reports indicate that these mesenchymal stem cells can differentiate into myocardium in vivo and in vitro. Due to the fact that it contributes to myocardial regeneration, the transplantation of mesenchymal stem cells is expected to be a breakthrough treatment to heal myocardial injury and prevent heart failure after injury. However, the low survival rate of mesenchymal stem cells transplanted into injured myocardial tissue is a limitation of cell therapy.
  • the survival rate of stem cells transplanted into the injured myocardium is known to be less than 1%, suggesting that the effectiveness of stem cell therapy, which has been clinically tried in myocardial infarction disease, is not greater than expected. It is believed that one of the causes of stem cell death after transplantation is due to the low adhesion between the transplantation site and the transplanted cells, which is believed to weaken the signaling mechanisms associated with cell survival and differentiation.
  • the inventors of the present invention while applying the appropriate stimulation to the stem cells, while studying a method for increasing the adhesion of the stem cells, when the protein kinase C activator is treated to the stem cells, the adhesion and spreading capacity of the stem cells increases It was confirmed that the adhesion of stem cells in the implantation site, such as to complete the present invention.
  • Another object of the present invention is to provide a stem cell enhanced adhesion, treated with a protein kinase C activator.
  • Another object of the present invention is to provide a pharmaceutical composition for treating heart disease, comprising as an active ingredient stem cells having increased adhesion ability treated with a protein kinase C activator.
  • the present invention provides a composition for promoting stem cell adhesion and stem cell adhesion promoting method comprising a protein kinase C activator as an active ingredient.
  • the present invention provides a stem cell enhanced adhesion ability, treated with a protein kinase C activator.
  • the present invention provides a pharmaceutical composition for treating ischemic heart disease comprising stem cells having increased adhesion ability treated with a protein kinase C activator as an active ingredient.
  • Protein kinase C activator promotes the phosphorylation of FAK (focal adhesion kinase), a signaling molecule associated with cell adhesion in stem cells, paxillin, Tallinn, vinculin and GTase
  • FAK focal adhesion kinase
  • Rac1 phosphorus By increasing the expression of Rac1 phosphorus, there is an excellent effect to effectively attach stem cells to the site of transplanted myocardial damage.
  • Figure 2 is a diagram showing the spreading capacity of mesenchymal stem cells according to PMA treatment (* p ⁇ 0.05 vs. control).
  • Figure 3 is a diagram showing the results confirmed by the separation rate of the mesenchymal stem cells according to PMA treatment by trypsinization assay (* p ⁇ 0.05 vs. control).
  • Figure 4 shows the spread (a) and adhesion (b) of mesenchymal stem cells after treatment with mesenchymal stem cells with protein kinase C (PKC) activator (PMA) and inhibitor (rotlerin).
  • PKC protein kinase C
  • PMA protein kinase C activator
  • Rotlerin inhibitor
  • FIG. 5 and 6 show the attachment of mesenchymal stem cells following treatment with PKC activator (PMA) and inhibitor (rotlerin) in fibronectin secondary structure (FIG. 5), cardiogel tertiary structure (FIG. 6).
  • PMA PKC activator
  • rotlerin inhibitor
  • FIG. 6 Fig. 5 * p ⁇ 0.001 vs. DMSO, * * p ⁇ 0.001 vs. PMA, p ⁇ 0.005 vs. DMSO and p ⁇ 0.005 vs. PMA
  • Fig. 6 ⁇ p ⁇ 0.01 vs. DMSO, ⁇ p ⁇ 0.01 vs. PMA, ⁇ p ⁇ 0.05 vs. DMSO and ⁇ p ⁇ 0.005 vs. PMA Bar: 100 ⁇ m
  • FIG. 7 shows phosphorylation of FAK, a cell adhesion-associated signaling molecule, paxillin (B), and talin (C) following treatment with PKC activator (PMA) and inhibitor (rotlerin).
  • PMA PKC activator
  • rotlerin inhibitor
  • Figure 8 shows the results of confirming the expression changes of Rac1 following treatment with PKC activator (PMA) and inhibitor (rotlerin) (* p ⁇ 0.01 vs. untreated group and * * p ⁇ 0.05 vs. PMA-treated) group).
  • FIGS. 9 to 12 are diagrams showing the results of confirming the intracellular location of adhesion-related molecules using double immunostaining (vinculin and p-FAK (FIG. 9), integrin ⁇ 5 and paxillin (FIG. 10), integrin ⁇ v ⁇ 3 and paxillin (FIG. 11), vinculin and integrin ⁇ V (FIG. 12)) (Bar: 50 ⁇ m).
  • Figure 13 is a diagram confirming the location and viability of the mesenchymal stem cells after transplantation into the rat mesenchymal stem cells pre-treated with PMA.
  • FIG. 14 is a diagram showing the results of measuring the size change of the myocardial infarction of the heart transplanted with PMA-treated mesenchymal stem cells through TTC staining.
  • 15 is a diagram showing the results of measuring the fiber formation site of the heart implanted with PMA-treated mesenchymal stem cells by Masson's trichrome staining.
  • Figure 16 shows the change in the development of dead cardiomyocytes showing a TUNEL-positive response following transplantation of PMA-treated mesenchymal stem cells using a TUNEL assay.
  • the present invention provides a composition for promoting cell adhesion, comprising a protein kinase C (PKC) activator as an active ingredient.
  • PLC protein kinase C
  • PKC activator when processed in stem cells, activates PKC, promotes phosphorylation of FAK, involved in cell adhesion-related signal transduction, paxillin, talin, vinculin By promoting the expression of the stem cells can be effectively attached to the site of implanted heart damage.
  • the PKC activator is not particularly limited in kind, and may be preferably PMA (phorbol myristate acetate) or diacylglycerol.
  • the PKC activator is preferably included at a concentration of 50 to 500 nM, more preferably may be included at a concentration of 100 nM.
  • the stem cells may include adult stem cells, embryonic stem cells, mesenchymal stem cells, adipose stem cells, hematopoietic stem cells, cord blood stem cells and dedifferentiated stem cells, preferably mesenchymal stem cells.
  • the mesenchymal stem cells can be used regardless of where they originate from.
  • Mesenchymal stem cells can be obtained from known mesenchymal stem cell sources, for example bone marrow, tissue, embryo, umbilical cord blood, blood or body fluids.
  • Animals to be harvested such as bone marrow and tissue may be mammals, and when the animal is a human, bone marrow, tissue, etc., are administered as a cell therapy, stem cells having increased adhesion by treatment with the protein kinase C activator of the present invention. It may be the patient's own or someone else's. Methods for obtaining mesenchymal stem cells from such known mesenchymal stem cell sources are well known in the art.
  • Attachment of the stem cells means that the stem cells to be transplanted are transplanted to a transplantation site that is in need of treatment, preferably a heart injury site.
  • a transplantation site that is in need of treatment, preferably a heart injury site.
  • the survival rate of the transplanted stem cells increases. It can effectively treat heart disease.
  • the present invention provides a method for promoting stem cell adhesion, characterized in that the protein kinase C (hereinafter, PKC) activator is treated to the stem cells.
  • PKC protein kinase C
  • the method of treating the stem cells with the PKC activator is not particularly limited, and any method may be used as long as the method allows PKC in the stem cells to be activated by contacting the stem cell with the PKC activator for a predetermined time.
  • the treatment of the PKC activator can be performed by culturing stem cells in a medium containing the PKC activator.
  • the medium may include a medium generally used in the culture of stem cells.
  • a medium may include, for example, Minimum Essential Medium alpha (MEM-alpha), Mesenchymal Stem Cell Growth Medium (MSCGM), Dulbecco's Modified Eagle's Medium (DMEM), and the like.
  • MEM-alpha Minimum Essential Medium alpha
  • MSCGM Mesenchymal Stem Cell Growth Medium
  • DMEM Dulbecco's Modified Eagle's Medium
  • the attachment of the stem cells may be characterized in that the cardiac cell damage site, the heart cells include all cells in the process of differentiation into cardiomyocytes or cardiomyocytes.
  • the present invention also provides a pharmaceutical composition for treating ischemic heart disease comprising a stem cell increased adhesion ability treated with a protein kinase C activator, and the same as an active ingredient.
  • Stem cells with increased adhesion capacity are characterized by increased phosphorylation of focal adhesion kinase (FAK) and increased expression of Rac1, which is paxillin, tallin, vinculin, and GTase.
  • FAK focal adhesion kinase
  • the ischemic heart disease may include angina or myocardial infarction.
  • the stem cells may be used for transplantation as it is, and may be transplanted as a composition to which various agents are added or genes are introduced to improve the treatment efficiency according to the transplantation.
  • composition of the present invention for example, 1) the addition of a substance that enhances the cell proliferation rate of the present invention or promotes further differentiation into cardiac cells, or the introduction of a gene having such an effect, 2) the present invention The addition of a substance that improves the survival rate in the damaged area of cells, or the introduction of a gene having such an effect, 3) the addition of a substance that prevents the adverse effects of the cells of the present invention from damaged tissues, or such effects.
  • the method of administering stem cells of the present invention is not particularly limited, and for example, topical administration, intravenous administration, intraarterial administration, and the like can be used.
  • cell transplantation into a patient can be administered by any route as long as it can induce migration to the disease site.
  • the cells to be transplanted may be collected by collecting them in a syringe in a suspended state using physiological saline, etc., exposing tissue damaged by surgery, and injecting directly into the damaged area with a needle. Consideration may be given to loading into a vehicle having a means for directing the lesion.
  • the activated stem cells of the invention may be topical (including buccal, sublingual, skin and intraocular administration), parenteral (including subcutaneous, intradermal, intramuscular, instillation, intravenous, intraarterial, intraarticular and cerebrospinal fluid) or Administration can be via several routes including percutaneous administration, preferably parenteral administration, most preferably direct to the affected area.
  • the pharmaceutical composition of the present invention can be used as a cell therapeutic agent, and the cell therapeutic agent is a drug used for the purpose of treatment, diagnosis, and prevention by cells and tissues prepared through isolation, culture, and special manipulation from humans (US FDA regulation).
  • the cell therapeutic agent is a drug used for the purpose of treatment, diagnosis, and prevention by cells and tissues prepared through isolation, culture, and special manipulation from humans (US FDA regulation).
  • US FDA regulation for the purpose of treatment, diagnosis, and prevention through a series of actions such as proliferating and screening live autologous, allogeneic, or heterologous cells in vitro or otherwise altering the biological properties of the cells to restore the function of the cells or tissues.
  • composition of the present invention may further comprise a pharmaceutically acceptable carrier, excipient and diluent in addition to the active ingredient described above for administration.
  • carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil.
  • compositions of the present invention may be prepared in various parenteral or oral administration forms according to known methods.
  • isotonic aqueous solutions or suspensions are preferred for injectable formulations.
  • injectable formulations may be prepared according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • each component may be formulated for injection by dissolving in saline or buffer.
  • the effective dosage of the pharmaceutical composition of the present invention may vary depending on the age and gender of the patient, but may be administered to the subject by suspending in a suitable diluent at a concentration of 4x10 5 to 4x10 10 cells / ml, preferably 4x10 7 cells. It can be used by suspending at a concentration of / ml.
  • the diluent is used for the purpose of protecting and maintaining the cells and facilitating their use when injected into the desired tissue.
  • the diluent may be a saline solution, a phosphate buffer solution, a buffer solution such as HBSS, plasma or blood components.
  • composition of the present invention can be used alone or in combination with methods using surgery, chemical therapy, radiotherapy, hormone therapy, drug therapy and biological response modifiers for the treatment of ischemic heart disease.
  • Mesenchymal stem cells were collected by extracting bone marrow-derived mesenchymal stem cells from the femur and tibia of a 4 week old male Sprague-Dawley rat (about 100 g). The obtained mesenchymal stem cells were cultured in 10 ml of medium consisting of DMEM (Dulbecco's modified Eagle's medium) to which 10% fetal bovine serum, 1% penicillin and streptomycin solution were added.
  • DMEM Dynamicin-derived mesenchymal stem cells
  • the bone marrow isolated from the upper layer of 1.073 g / ml percoll was added and centrifuged to wash the mononuclear cells obtained at the interface twice, and then mixed with 10% FBS-DMEM and dispensed into the flask at 1 ⁇ 10 6 cells / 100 cm 2 . . Incubation was in a Forma Scientific incubator with 37 ° C., 95% air, 5% CO 2 . After 48 to 72 hours, nonadsorbent cells were removed and adsorbent cells were washed twice with PBS. Fresh medium was added and cultured with changing medium every 3-4 days for about 10 days. In order to obtain only mesenchymal stem cells, immunophenotyping was performed using various markers on the cell surface and cells.
  • the cells were washed with PBS and labeled with the FITC-attached antibodies (CD14, CD34, CD71, CD90, CD105, CD106, ICAM-1). Goat anti-mouse IgG (goat anti-mouse IgG) with FITC was used as a secondary antibody. Labeled cells were identified using a flow cytometer, and the results were analyzed using Cell Quest Pro Software. The mesenchymal stem cells obtained were used for in vivo and in vitro experiments in passage 2 and passage 3 cells.
  • mesenchymal stem cells were suspended, 2 x 10 4 cells were added to each well in a 6 well plate. The cells were allowed to adhere to the plate at 37 ° C. and 5% CO 2 for 1 hour. Subsequently, phorbol 12-myristate 13-acetate (PMA), a protein kinase C (hereinafter, PKC) activator, was treated for 2 to 8 hours, and the attachment of mesenchymal stem cells was determined by an adhesion assay and spread analysis. It was confirmed using (spreading assay). At this time, DMSO was treated to mesenchymal stem cells as a control.
  • PMA phorbol 12-myristate 13-acetate
  • PKC protein kinase C
  • mesenchymal stem cells were treated with PMA (20, 50, 100, 200, 500 nM) at various concentrations, and then carefully washed the mesenchymal stem cells with PBS three times. Four different parts were taken using a phase contrast microscope. All experiments were performed using three different wells and repeated three times.
  • the cells were incubated at 37 ° C. and 5% CO 2 conditions in 4 wells for 4 hours, washed three times with PBS, and fixed with 3% formaldehyde (formaldehyde). Fixed cells were stained with coomassie blue and residual material was removed. Finally, four parts were photographed with a phase contrast microscope.
  • mesenchymal stem cells treated with PKC promoter, PMA increased the ability to spread by 4.5 times compared to the control.
  • the mesenchymal stem cells were cultured for one day, and then treated with PMA for 4 hours and a trypsinization assay was performed. Cells were plated about 90% and trypsinized at 37 ° C. for 3 minutes. The fallen cells were washed away, and the cells attached to the plates were incubated at 37 ° C. for 1 hour, and then nine cells were counted per plate.
  • mesenchymal stem cells treated with PMA significantly reduced the separation rate compared to the control.
  • mesenchymal stem cells were treated with PMA, a PKC activator, and rottlerin, a PKC activity inhibitor, The adhesion and spreading ability of stem cells were compared with the control.
  • the adhesion of mesenchymal stem cells treated with PMA, a PKC activator was increased, and the adhesion with rottlerin, an activity inhibitor, decreased.
  • the experimental group treated with PMA and rottlerin at the same time confirmed the adhesion capacity similar to the control group (a).
  • the experimental group treated with PMA showed a separation ratio of about 25% compared to the control group (b).
  • Fibroblasts and Vitronectin are components of the extracellular matrix and are involved in cell growth and differentiation. Therefore, in order to confirm whether the PKC activator can play a functional role in the environment after in vivo culture, an experiment using a substrate having a tertiary structure was performed using a cardiogel.
  • Cardiogel a substrate of tertiary structure derived from cardiac fibroblasts, used a method modified from the method of Cukierman 39 . Cardiogel simulates the cardiomyocyte environment using fibroblasts from the heart. Cardiogels were dispensed at 2 ⁇ 10 5 in a 35 mm dish and the medium was changed every 48 hours until tissue deprived of cell characteristics.
  • cardiogel is a tertiary structure, it may be different from the adhesion ability in the secondary structure. Therefore, in order to confirm the adhesion ability of mesenchymal stem cells by PMA treatment, which is a PKC activator in a three-dimensional cardiogel and a fibronectin matrix of secondary structure, the mesenchymal stem cells were cultured on a fibronectin-coated plate and treated with PMA. Then incubated for 2 and 16 hours or in cardiogel for 2 and 16 hours. After incubation, the appearance of the cells was observed under a control microscope.
  • PMA treatment which is a PKC activator in a three-dimensional cardiogel and a fibronectin matrix of secondary structure
  • Protein concentration was measured using a Bradford Protein assay kit (Bio-Rad Laboratories, Richmond, CA). The same amount of protein from the whole cell lysate was lowered on 12% SDS-PAGE and then transferred to a polyvinylidene difluoride (PVDF) membrane. 5% fat-free dry milk was added to Tris-buffered saline-Tween 20 (TBS-T, 0.1% Tween20) to block the membrane at room temperature for one hour. The membrane was washed twice with TBS-T and then the primary antibody was reacted at room temperature for 1 hour or overnight at 4 ° C.
  • TBS-T Tris-buffered saline-Tween 20
  • the mixture was wiped with TBS-T three times for 10 minutes, and incubated for 45 minutes by adding a secondary antibody bound to horseradish peroxidase (HRP) at room temperature. After performing the washing process once again, the band was confirmed by ECL reagent (enhanced chemiluminescence reagent, Santa Cruz Biotechnology). The intensity of the band was measured using a photo-image system (molecular dynamics, Sunnyvale, CA).
  • the phosphorylation of focal adhesion kinase (FAK), a signaling molecule associated with cell adhesion, was increased by 28.5% by treatment of PMA, a PKC activator (A), paxillin (B), The expressions of talin (C) and vinculin (D) were also markedly increased by 46.2%, 33% and 20%, respectively. This increase in expression was reduced by treatment with Rotlin, a PKC activity inhibitor. However, when the PKC activator and the inhibitor were treated simultaneously, the phosphorylation of FAK increased by 50%, and the expression of paxillin, thallin, and vinculin increased by 50%, 45%, and 47.5%, respectively, compared to the PKC activity inhibitor alone group. Confirmed.
  • Rho GTPases can be achieved by measuring the expression of Rac1.
  • PKC affects the actin cytoskeleton through its effects on Rho GTPases, and in cell spreading, Rac1 is located under the mechanism of PI3-kinase and PKC, which include the function of the integrin cytoplasmic domain.
  • PMA a PKC activator
  • Double immunostaining was used to determine whether the adhesion-related molecules were in the same position in the cell.
  • Cells were grown in 4-well plastic petri dishes and washed twice with PBS. Then, 0.5 ml of 4% paraformaldehyde diluted in PBS was added thereto and reacted for 30 minutes. The cells were washed with PBS again and the cells were permeated with PBS containing 0.2% Triton X-100. Integrin ⁇ 5, integrin ⁇ v ⁇ 3, integrin ⁇ V, p-FAK, paxillin and vinculline primary antibodies were added to cells blocked with PBS containing 10% goat serum.
  • the cells were washed with PBS three times for 10 minutes, followed by attaching secondary goat anti-rabbit IgG with fluorescein isothiocyanate (FITC) and goat anti-mouse IgG with Texas red for 1 hour. All photographs were identified by light fluorescence microscopy (LSM 700, Carl Zeiss. Thomwood, NY) using an excitation filter.
  • FITC fluorescein isothiocyanate
  • Figs. 9-12 vinculin and p-FAK (Fig. 9), integrin ⁇ 5 and paxillin (Fig. 10), integrin ⁇ v ⁇ 3 and paxillin (Fig. 11) and vinculin by treatment with PKC modulators. It was confirmed that the strength of the overlap between and integrin ⁇ V (FIG. 12) was increased by treatment with PMA, an inhibitor of PKC activity. The intensity of overlap signal was lower in the stem cells treated with PKC inhibitor, Rotlerin, compared to the control group, and similar to the control group in the stem cells treated with PKC activator and inhibitor at the same time.
  • mesenchymal stem cells labeled with DAPI 4 ', 6'-diamidine-2'-phenylindole dihydrochloride
  • DAPI ', 6'-diamidine-2'-phenylindole dihydrochloride
  • Mesenchymal stem cells were labeled with DAPI and the sterile DAPI solution was transplanted on the same day as the cell transplanted for 30 minutes until the final concentration was 50 ⁇ g / ml. Cells were washed 6 times with PBS and cells without DAPI were removed. Cells labeled with DAPI were detached with 0.25% trypsin, and cells to be used for transplantation were suspended in medium without serum. After inducing myocardial infarction, cells suspended in 1 ⁇ 10 6 mesenchymal stem cells in 100 ⁇ l serum-free medium were transplanted using a 30 gauge needle. Cells were injected into the front and side of the interface without infarction.
  • Rats implanted were used.
  • One experimental group injected mesenchymal stem cells stained with DAPI and measured the survival of mesenchymal stem cells after 3 days. And then, the mesenchymal stem cells were transplanted into two experimental groups and used for analyzing the cell shape after one week. The other experimental groups were used for cardiac function evaluation after three weeks.
  • mesenchymal stem cells pretreated with PMA adhered to the border region of the infarct and the normal portion, and most of the mesenchymal stem cells were attached to the infarct border region of the left ventricle as compared with the control group.
  • the number of DAPI-labeled cells was confirmed to be higher than that of the PMA pretreatment group, which indicates that mesenchymal stem cells can be effectively attached by PMA treatment.
  • the heart was extracted.
  • the heart was perfused with 10% (v / v) neutral buffered formaldehyde for 24 hours, fixed, cut horizontally, and soaked in paraffin as usual.
  • the slices cut to a thickness of 5 ⁇ m were coated on gelatin-coated glass slides so that staining could work well on the continuous sections of the tissue at the implant site.
  • TTC (2,3,5-Triphenyltetrazolium chloride) staining was used to measure cardiac tissue viability and myocardial infarction size.
  • the tissues were cut and immersed in 1% TTC (Sigma, St. Louis, MO) solution at pH 7.4 and placed at 37 ° C. for 20 minutes. Tissues were placed in 10% formalin and left overnight at 4 ° C. The heart was cut transversely and the percent infarct size was calculated at what percentage of the total left ventricle. Both tissues stained with TTC were photographed with a digital camera.
  • the model of the mesenchymal stem cells pretreated with PMA significantly reduced the size of myocardial infarction compared with the untreated control.
  • Fibrosis was analyzed using Masson's trichrome staining method. Fibrotic sites of the group injected with PMA-treated mesenchymal stem cells were measured using metamophor, and the expression rate was measured against the total left ventricle.
  • TUNEL assay Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay
  • TUNEL assay was performed according to the manufacturer's method (Chemicon International, Temecula, CA). Paraffin of 5 ⁇ m thick tissue was removed and rehydrated and washed with PBS. The sections were then treated with 3.0% H 2 O 2 and then treated with terminal deoxynucleotidyl transferase (TDT) enzymes at 37 ° C. for 1 hour. Subsequently, nucleotides with digoxigenin were reacted at 37 ° C. for 30 minutes.
  • 3,3-DAB (3,3-diamino benzidine Vector Laboratories, Burlingame, Calif.) was treated for 5 minutes. Finally, the sections were counterstained with methyl green, covered with coverslip, and observed under an optical microscope. Each group made 5 sections and observed at 5 different sites.
  • the function of the heart in rats implanted with PMA treated mesenchymal stem cells calculated using the pressure-volume ring was shown to gradually improve after myocardial infarction.
  • the ejection fraction (EF), stroke volume (SV), cardiac output (cardiac output) was significantly increased in the group transplanted with PMA pretreated mesenchymal stem cells compared to the control group.
  • PMA-treated mesenchymal stem cell transplanted rats had increased LV function.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention porte sur une composition comprenant un activateur de la protéine kinase C permettant de favoriser l'adhérence de cellules souches ainsi que sur une méthode permettant de favoriser l'adhérence de cellules souches. L'activateur de la protéine kinase C selon la présente invention favorise la phosphorylation de la kinase d'adhérence focale (FAK) qui consiste en une molécule de transduction du signal associée à la capacité d'adhérence cellulaire des cellules souches, et accroît l'expression de la paxilline, de la taline, de la vinculine et de Rac1 qui est une GTPase, et permet ainsi aux cellules souches d'adhérer efficacement à une zone endommagée du myocarde.
PCT/KR2012/007308 2012-09-12 2012-09-12 Composition comprenant un activateur de la protéine kinase c destiné à favoriser l'adhérence de cellules souches et méthode destinée à favoriser l'adhérence de cellules souches WO2014042292A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2012/007308 WO2014042292A1 (fr) 2012-09-12 2012-09-12 Composition comprenant un activateur de la protéine kinase c destiné à favoriser l'adhérence de cellules souches et méthode destinée à favoriser l'adhérence de cellules souches

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2012/007308 WO2014042292A1 (fr) 2012-09-12 2012-09-12 Composition comprenant un activateur de la protéine kinase c destiné à favoriser l'adhérence de cellules souches et méthode destinée à favoriser l'adhérence de cellules souches

Publications (1)

Publication Number Publication Date
WO2014042292A1 true WO2014042292A1 (fr) 2014-03-20

Family

ID=50278390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/007308 WO2014042292A1 (fr) 2012-09-12 2012-09-12 Composition comprenant un activateur de la protéine kinase c destiné à favoriser l'adhérence de cellules souches et méthode destinée à favoriser l'adhérence de cellules souches

Country Status (1)

Country Link
WO (1) WO2014042292A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220062345A1 (en) * 2018-11-09 2022-03-03 Corestem Co.,Ltd. Pharmaceutical composition containing protein kinase c activator-treated stem cells or culture thereof for preventing or treating autoimmune diseases
WO2023282424A1 (fr) * 2021-07-06 2023-01-12 건국대학교 산학협력단 Vésicules extracellulaires dérivées de cellules souches et leur utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060108658A (ko) * 2003-11-06 2006-10-18 사노피-아벤티스 도이칠란트 게엠베하 허혈성 심장질환의 세포 치료에 사용되는 ｅＮＯＳ 전사강화제
KR20090025989A (ko) * 2007-09-07 2009-03-11 부산대학교 산학협력단 조직재생능이 향상된 중간엽 줄기세포 및 그의 제조방법
KR20090045940A (ko) * 2006-08-29 2009-05-08 포휴먼텍(주) 세포자멸사의 억제를 위한 약학 조성물, 및 이를 전달하는 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060108658A (ko) * 2003-11-06 2006-10-18 사노피-아벤티스 도이칠란트 게엠베하 허혈성 심장질환의 세포 치료에 사용되는 ｅＮＯＳ 전사강화제
KR20090045940A (ko) * 2006-08-29 2009-05-08 포휴먼텍(주) 세포자멸사의 억제를 위한 약학 조성물, 및 이를 전달하는 방법
KR20090025989A (ko) * 2007-09-07 2009-03-11 부산대학교 산학협력단 조직재생능이 향상된 중간엽 줄기세포 및 그의 제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHOI, EUN JU: "Enhancement of mesenchymal stem cell adhesion by PKC activation", MASTER'S THESIS, February 2011 (2011-02-01), YONSEI UNIVERSITY GRADUATE SCHOOL *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220062345A1 (en) * 2018-11-09 2022-03-03 Corestem Co.,Ltd. Pharmaceutical composition containing protein kinase c activator-treated stem cells or culture thereof for preventing or treating autoimmune diseases
WO2023282424A1 (fr) * 2021-07-06 2023-01-12 건국대학교 산학협력단 Vésicules extracellulaires dérivées de cellules souches et leur utilisation

Similar Documents

Publication Publication Date Title
JP6321610B2 (ja) 神経変性を治療するための方法及び組成物
JP5968442B2 (ja) 心筋梗塞の修復再生を誘導する多能性幹細胞
US20090169527A1 (en) Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors
US10870830B2 (en) Method for culturing differentiation-promoting and -sustaining spheroid form of tonsil-derived stem cells
WO2020111507A1 (fr) Composition pour la transplantation d'organoïde
US20120020925A1 (en) Therapeutic Use of Specialized Endothelial Progenitor Cells
KR20080049917A (ko) 인간 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는,신경전구세포 또는 신경줄기세포의 신경세포로의 분화 및증식 유도용 조성물
CN103237887A (zh) 胚胎干细胞来源的心肌细胞以及包含所述心肌细胞作为活性成分的细胞治疗剂
WO2014042292A1 (fr) Composition comprenant un activateur de la protéine kinase c destiné à favoriser l'adhérence de cellules souches et méthode destinée à favoriser l'adhérence de cellules souches
WO2020242250A1 (fr) Composition pharmaceutique pour favoriser l'ostéogenèse, comprenant des mitochondries dérivées d'ostéoblastes
WO2017131353A1 (fr) Procédé d'induction de la transdifférenciation des fibroblastes en chondrocytes
BRPI0708039A2 (pt) células alimentadoras derivadas de células-tronco de tecido
WO2017078439A1 (fr) Composition pharmaceutique pour le traitement du diabète, comprenant des cellules d'îlots pancréatiques et une matrice extracellulaire artificielle de type élastine
WO2020101185A1 (fr) Feuillet de cellules souches dérivées du tissu adipeux pour la transplantation préserntant une angiogenèse accrue par co-culture 3d, et procédé de production de celui-ci
WO2018088821A1 (fr) Composition favorisant l'activité des cellules souches, comprenant un inhibiteur d'histone désacétylase et un facteur d'amorçage en tant que principes actifs
WO2021158045A1 (fr) Composition pour injection intra-péricardique comprenant des cellules souches et son utilisation
US20230142705A1 (en) Use of anti-aging glycopeptides for inhibition of immune rejection of a graft
WO2021010702A1 (fr) Composition pour la régénération d'une plaque de croissance
WO2020262916A1 (fr) Composition pour le traitement d'une maladie artérielle périphérique
US20150025031A1 (en) Metabolic downregulation for cell survival
WO2018203651A9 (fr) Construction biopsique 3d basée sur des cellules souches mésenchymateuses dérivées du cornet nasal inférieur du nez humain et son utilisation
WO2012044139A2 (fr) Nouvelle utilisation de la cryptotanshinone
AU2003205141B2 (en) Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors
WO2017065370A1 (fr) Composition contenant de l'apicidine pour l'induction de la différenciation de cellules souches en cellules ressemblant à des myocardiocytes
Zhang et al. A novel population of human bone marrow multipotent mesenchymal stem cells regenerates infarcted myocardium in rats

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12884563

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12884563

Country of ref document: EP

Kind code of ref document: A1